Key facts
- Glytec’s last known valuation is $106.0M (May 2020).
- It has raised $135.9M; the latest was Later Stage VC ($36.0M) in Jun 2025.
- Notable investors include CalAtlantic Group, Hayfin Capital Management, Savitr Capital, Sea Dragon Healthcare Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Glytec
- ·The full record, as it builds
Funding rounds
No funding rounds for Glytec are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Glytec
Developer of a cloud-based insulin management platform designed to improve diabetes care and insulin dosing in clinical settings. The company offers FDA-cleared, integrated software supported by patented technology and real-time decision support tools, enabling hospitals and healthcare providers to enhance patient safety, reduce readmissions, and streamline clinical workflows.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2006
- Employees
- 79
- Website
- glytec.com/
- Ownership
- Privately Held (backing)
Glytec doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Glytec shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Glytec in its N-PORT filings yet. We sweep new filings monthly.